Welcome to the Goncharova Lab, part of UC Davis Health's Department of Internal Medicine and Division of Pulmonary, Critical Care and Sleep Medicine. Our research interests have focused on the molecular and cellular mechanisms of pulmonary hypertension. Our goals are:

-to dissect new signaling hubs driving hyper-proliferation of resident pulmonary vascular cells, pulmonary vascular remodeling and PAH;

-to identify and pre-clinically validate novel molecular target pathways for therapeutic intervention;

-to develop in vitro human-based models for molecular and pre-clinical studies.

Goncharova Lab Research Example

  1. The role of mTOR signaling network and growth suppressor TSC2 in pulmonary vascular cell reprograming, PA remodeling and right ventricular dysfunction in pulmonary arterial hypertension.
  2. The role of HIPPO signaling cassette in pulmonary vascular cell hyper-proliferation, development and progression of pulmonary hypertension.
  3. GATA6 transcriptional factor as a regulator of pulmonary vascular cell-cell communications, BMP signaling and inflammation in pulmonary hypertension.
  4. Lipid metabolism as a regulator of pulmonary vascular remodeling and pulmonary hypertension.

Elena Goncharova head shot

Elena Goncharova, PhD

Professor

Director, Pulmonary Vascular Disease Program,  UC Davis Lung Center

Tatiana Kudryash headshot

Tatiana Kudryashova, PhD

Assistant Adjunct Professor

Dmitry Goncharov, MS

Staff Research Associate III

Lab Manager

Yuanjun (Steven) Shen, PhD

Postdoctoral Researcher

Lifeng Jiang, PhD

Postdoctoral Researcher

Derek Lin, B.S.

Lab Assistant

Aisha Saiyed

Undergraduate Researcher

Click here to see a complete list of published work.

Selected Publications:

  • Goncharov DA, Kudryashova TV, Ziai H, Ihida-Stansbury K, DeLisser H, Krymskaya VP, Tuder RM, Kawut SM, Goncharova EA: mTORC2 coordinates pulmonary artery smooth muscle cell metabolism, proliferation and survival in pulmonary arterial hypertension. Circulation, 129(8):864-74, 2014
  • Kudryashova TV#, Goncharov DA#, Pena A, Kelly N, Vanderpool R, Baust J, Kobir A, Shufesky W, Mora AL, Morelli AE, Zhao J, Ihida-Stansbury K, Chang B, DeLisser H, Tuder RM, Kawut SM, Silljé HHW, Shapiro S, Zhao Y, Goncharova EA: HIPPO-integrin linked kinase crosstalk controls self-sustaining proliferation and survival in pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine, 194(7):866-877, 2016
  • Pena A#, Kobir A#, Goncharov D, Goda A, Vanderpool R, Baust J, Chang B, Mora AL, Gorcsan J III, Goncharova EA: Pharmacological inhibition of mTOR kinase reverses right ventricle remodeling and improves right ventricle structure and function in rats. American Journal of Respiratory Cell and Molecular Biology 57(5):615-625, 2017
  • Goncharov DA, Goncharova EA, Tofovic SP, Hu J, Baust JJ, Pena AZ, Ray A, Rode A, Vanderpool RR, Mora AL, Gladwin MT, Lai YC: Metformin Therapy for Pulmonary Hypertension Associated with HFpEF versus PAH. American Journal of Respiratory and Critical Care Medicine 198(5):681-684, 2018
  • Kudryashova TV#, Shen Y#, Pena A, Cronin E, Okorie E, Goncharov DA, Goncharova EA: Inhibitory antibodies against Activin A and TGF-β reduce self-supported, but not soluble factors-induced growth of human pulmonary arterial vascular smooth muscle cells in pulmonary arterial hypertension. International Journal of Molecular Sciences 19(10), 2957, 2018
  • Farkas D, Thompson AAR, Bhagwani AR, Hultman S, Ji H, Kotha N, Farr G, Arnold ND, Braithwaite A, Casbolt H, Sabroe CGEI, Monaco C, Cool CD, Goncharova EA, Lawrie A, Farkas L: Toll-like receptor 3 is a therapeutic target for Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine 199(2):199-210, 2019
  • Shen Y, Goncharov DA, Avolio T, Ray A, Okorie E, Mora AL, Vanderpool R, Kudryashova TV, Goncharova EA: Differential effects of integrin-linked kinase inhibitor Cpd22 on severe pulmonary hypertension in male and female rats. Pulmonary Circulation 10(1): 2045894019898593, 2020
  • Daneva Z, Marziano C, Ottolini M, Chen YL, Hong K, Cope EL, Baker TM, Zhang A, Ta H, Mihalek AD,  Minshall RD, Kasetti RB, Shen Y, Zode GS, Goncharova EA, Laubach VE, Sonkusare SK: Endothelial Caveolin-1–TRPV4 channel signaling lowers pulmonary arterial pressure and is impaired in pulmonary hypertension. Proceedings of the National Academy of Science, 118(17):e2023130118, 2021
  • Sharifi-Sanjani M, Berman M, Goncharov D, Alhamaydeh M, Avolio TG, Baust J, Chang B, Kobir A, Ross M, St. Croix C, McTiernan C, Moravec CS, Goncharova EA#, Al Ghouleh I# (# equal senior author contribution): Yes-associated Protein (Yap) is Up-Regulated in Heart Failure and Promotes Cardiac Fibroblast Proliferation. International Journal of Molecular Sciences, 22(11):6164, 2021
  • Culley MK, Zhao J, Tai YY, Tang Y, Perk D, Negi V, Yu Q, Woodcock J, Handen A, Speyer G, Kim S, Lai YC, Satoh T, Watson A, Aaraj YA, Sembrat J, Rojas M, Goncharov D, Goncharova EA, Khan OF, Anderson DG, Dahlman JE, Gurkar A, Lafyatis R, Fayyaz A, Redfield M, Gladwin MT, Rabinovitch M, Gu M, Bertero T, Chan SY: Frataxin deficiency promotes endothelial senescence in pulmonary hypertension.  Journal of Clinical Investigation, 131(11):e136459, 2021
  • Satoh T, Wang L, Levine A, Hahn S, Baust J, Wyman S, Salamacha N, Wu Y, Espinosa-Diez C, Reynolds M, Shiva S, St Hilaire C, Gomez D, Goncharov DA, Goncharova EA, Straub A, Lai YC, McTiernan CF, Gladwin MT: Metabolic syndrome mediates ROS-miR-193b-NFYA-dependent down regulation of sGC activity and contributes to exercise-induced pulmonary hypertension in HFpEF. Circulation 2021, Epub ahead of print

Reviews & Editorials

  • Goncharova EA: mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects. The FASEB Journal 27(5): 1796-1807, 2013
  • Goncharova EA, Gladwin MT, Kawut SM: Update in Pulmonary Vascular Diseases 2014. American Journal of Respiratory and Critical Care Medicine, 192(5): 544-550, 2015
  • Pullamsetti SS, Savai R, Seeger W, Goncharova EA: Translational Advances in the field of Pulmonary Hypertension. From cancer biology to new PAH therapeutics: Targeting cell growth and proliferation signaling hubs. American Journal of Respiratory and Critical Care Medicine, 195(4):425-437, 2017
  • Shen Y and Goncharova EA: TWISTed HIF: Re-visiting Smooth Muscle HIF-1α Signaling in Pulmonary Hypertension. American Journal of Physiology: Lung Cellular and Molecular Physiology 315(3):L387-L389, 2018
  • Lai YC, Provencher S., Goncharova EA: TAKling GDF-15 and Skeletal Muscle Atrophy in Pulmonary Hypertension: Are We There Yet?  Thorax 74(2):103-105, 2019
  • Spiekerkoetter E, Goncharova EA, Guignabert C, Stenmark K, Kwapiszewska G, Rabinovitch M, Voelkel N, Bogaard HJ, Graham B, Pullamsetti SS, Kuebler WM: Hot topics in Pulmonary Arterial Hypertension Disease Mechanisms: Cancer-like pathobiology, the role of the adventitia, systemic involvement, and right ventricular failure. Pulmonary Hypertension 9(4):2045894019889775, 2019
  • Goncharova EA, Simon MA, Yuan JXJ: mTORC1 in Pulmonary Arterial Hypertension: at the crossroads between vasoconstriction and vascular remodeling?  American Journal of Respiratory and Critical Care Medicine 201(10):1177-1179, 2020
  • Goncharova EA, Chan SY, Ventetuolo SE, Weissmann N, Schermuly RT, Mullin CJ, Gladwin MT: Update in pulmonary vascular diseases and right ventricular dysfunction in 2019 American Journal of Respiratory and Critical Care Medicine 202(1):22-28, 2020
  • August 2021: Congratulations to Dr. Shen on the American Heart Association Postdoctoral Award and the Jane Morse Award from the American Thoracic Society Pulmonary Circulation Assembly! Well done, Steve!